Ginkgo Bioworks Holdings, Inc. Cash Flow Statement
DNA / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Ginkgo Bioworks Holdings, Inc. used $171M in operating cash flow and negative free cash flow of $179M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$312.8M | -$547.0M | -$892.9M | -$2.1B | -$1.8B | -$126.6M | -$119.3M |
| Depreciation & Amortization | $59.0M | $63.0M | $70.5M | $42.6M | $29.1M | $13.9M | $10.8M |
| Operating Cash Flow | -$171.1M | -$319.6M | -$295.5M | -$252.2M | -$253.8M | -$135.8M | -$44.7M |
| Capital Expenditures | $7.7M | $62.5M | $40.8M | $52.3M | $56.5M | $57.8M | $22.2M |
| Free Cash Flow | -$178.7M | -$382.1M | -$336.3M | -$304.5M | -$310.3M | -$193.7M | -$66.9M |
| Share Buybacks | - | - | $0 | $0 | $25.0M | $0 | $408.0K |
| FCF Margin | -105.0% | -168.3% | -133.7% | -63.7% | -98.9% | - | - |